4.7 Article

Falls and the falls efficacy scale in Parkinson's disease

期刊

JOURNAL OF NEUROLOGY
卷 257, 期 7, 页码 1124-1128

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00415-010-5475-x

关键词

Parkinson's disease; Falls; Gait disorder; Patient safety

资金

  1. Acadia Pharmaceuticals
  2. Teva
  3. Ingelheim-Boehringer
  4. Glaxo Smith Kline
  5. Cephalon
  6. Valeant
  7. EMD Serono
  8. Novartis
  9. Pfizer
  10. NIH
  11. MJ Fox Foundation

向作者/读者索取更多资源

The purpose of this study was to investigate the relationship between fear of falling and fall frequency among patients with idiopathic Parkinson's disease (PD). One hundred-two participants with idiopathic PD were interviewed and examined. Participants reported the number of falls they had experienced in the preceding 3 months. They completed a mini-mental state exam (MMSE) and the falls efficacy scale (FES) questionnaire. Disease severity was determined by clinical examination using the Hoehn-Yahr staging system. Excluding two outliers who fell more than once each day, the subjects fell an average of 1.2 times in a 3 month period. There was a positive correlation between the number of falls, freezing of gait and Hoehn-Yahr score, and a negative correlation with the MMSE. In a post-hoc analysis the participants were divided into four groups based on fall frequency. The outliers had the lowest FES scores on average, similar to the scores seen in the rare fallers group. This study suggests that many factors are associated with fear of falling, including fall frequency, disease severity, and mental status. In the present study, the patients who fell the most often did not report the most fear. The lack of fear of falling but frequent falls in this small subgroup may suggest that special techniques to instill suitable caution to prevent falls are necessary, or may make training of these patients impossible.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据